SCHEDULE 13G/A: Sio Capital Management Discloses 5.04% Stake in Aprea Therapeutics
Beneficial Ownership Disclosure
Sio Capital Management, LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 5.04% in Aprea Therapeutics, Inc.'s common stock as of March 31, 2025.
Summary
- Sio Capital Management, LLC, a Delaware limited liability company and registered investment adviser, has filed an Amendment No. 2 to Schedule 13G regarding its ownership in Aprea Therapeutics, Inc.
- As of March 31, 2025, Sio Capital Management, LLC beneficially owned 276,603 shares of Aprea Therapeutics, Inc. common stock.
- This ownership represents 5.04% of the total outstanding common stock of Aprea Therapeutics, Inc.
- The percentage is based on 5,491,953 shares of common stock outstanding as of March 25, 2025, as reported in Aprea Therapeutics' Form 10-K.
- Sio Capital Management, LLC holds shared voting power and shared dispositive power over all 276,603 shares.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- Michael Castor, who controls Sio Capital Management, LLC and Sio GP, LLC, may be deemed to control the voting and dispositive decisions for these shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive ownership stake by an investment adviser in a biotechnology company. It does not provide specific insights into Aprea Therapeutics' operational performance or strategic direction, but rather reflects an investment decision by Sio Capital Management.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by an investment firm like Sio Capital Management could be viewed positively by other investors, signaling confidence in the company, or it could be neutral as it's a passive investment.
Key Dates
| Date | Description |
|---|---|
| 2025-03-25 | Date Aprea Therapeutics, Inc. reported 5,491,953 common shares outstanding in its Form 10-K filing. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-04-04 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Aprea Therapeutics, Sio Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.